Deramiocel

N/A

Report date: 2025/06/20 14:21:16

Base Information

Drug NameDeramiocel
Drug Alias NameAllogenic derived cellsAllogeneic CDCsAllogeneic adult stem cell therapy for myocardial infarctionAllogeneic cardiosphere-derived cellsCAP-1002
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Stem cell therapyCell and gene therapy > Cell therapy > Source of cells > Cardiosphere-derived
Mechanisms of ActionStem cell replacements
TargetsUpdating
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Genetic Diseases, X-LinkedGenetic Diseases, Inborn +[15] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaN/A
Originator CompaniesCapricor Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesCalifornia Institute For Regenerative MedicineCapricor Therapeutics IncMedical University Of South Carolina +[5] 
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Heart Failure, DiastolicHeart Failure +[5] 
Inactive IndicationsGenetic Diseases, X-LinkedGenetic Diseases, InbornMyocardial Infarction +[10] 

Other Information

ATC CodeN/A
Related LinksN/A